{"id":39592,"date":"2017-01-20T11:00:58","date_gmt":"2017-01-20T02:00:58","guid":{"rendered":"http:\/\/www.veeva.com\/jp\/?p=39592"},"modified":"2017-01-19T16:04:08","modified_gmt":"2017-01-19T07:04:08","slug":"top-global-pharma-companies-establish-new-industry-standards-group","status":"publish","type":"post","link":"https:\/\/pantheon.veeva.com\/jp\/news\/top-global-pharma-companies-establish-new-industry-standards-group\/","title":{"rendered":"\u30b0\u30ed\u30fc\u30d0\u30eb\u88fd\u85ac\u5927\u624b\u3001\u696d\u754c\u6a19\u6e96\u5316\u56e3\u4f53\u3092\u65b0\u305f\u306b\u7acb\u3061\u4e0a\u3052"},"content":{"rendered":"<p style=\"text-align: right;\">2017\u5e741\u670820\u65e5<\/p>\n<p style=\"text-align: right;\">Align Biopharma<\/p>\n<p>Veeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b Veeva)\u304a\u3088\u3073\u30b0\u30ed\u30fc\u30d0\u30eb\u88fd\u85ac\u4f01\u696d\u6700\u5927\u624b25\u793e\u306e\u3046\u30616\u793e\u304c\u53c2\u753b\u3057\u3001\u533b\u7642\u5f93\u4e8b\u8005\u3068\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u306e\u9023\u643a\u306e\u8fc5\u901f\u5316\u304a\u3088\u3073\u7c21\u4fbf\u5316\u3092\u76ee\u6307\u3057\u3001\u696d\u754c\u6a19\u6e96\u5316\u3092\u63a8\u9032\u3059\u308b\u56e3\u4f53\u300c<a href=\"http:\/\/www.alignbiopharma.org\/\">Align Biopharma<sup>TM<\/sup><\/a>\u300d\u8a2d\u7acb\u3092\u767a\u8868\u3044\u305f\u3057\u307e\u3057\u305f\u3002\u696d\u754c\u5404\u65b9\u9762\u306e\u610f\u898b\u3092\u53c2\u8003\u306b\u3057\u306a\u304c\u3089\u3001\u8a2d\u7acb\u30e1\u30f3\u30d0\u30fc\u4f01\u696d\u304c\u88fd\u85ac\u4f01\u696d\u5411\u3051\u306b\u30aa\u30fc\u30d7\u30f3\u306a\u6a19\u6e96\u306e\u7b56\u5b9a\u304a\u3088\u3073\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u958b\u767a\u3092\u884c\u3044\u3001\u533b\u7642\u5f93\u4e8b\u8005\u304c\u5fc5\u8981\u3068\u3059\u308b\u533b\u85ac\u54c1\u60c5\u5831\u3068\u6cbb\u7642\u60c5\u5831\u306e\u63d0\u4f9b\u7d4c\u8def\u3092\u5408\u7406\u5316\u3057\u3066\u60a3\u8005\u30b1\u30a2\u306e\u5411\u4e0a\u3092\u56f3\u308a\u307e\u3059\u3002(\u672c\u30ea\u30ea\u30fc\u30b9\u306f\u3001Veeva\u7c73\u56fd\u672c\u793e\u304c\u767a\u8868\u3057\u305f\u5831\u9053\u8cc7\u6599\u306e\u6284\u8a33\u3067\u3059)<\/p>\n<p>\u30a2\u30e9\u30ac\u30f3\u793eGlobal Commercial\u3001IT\u90e8\u9580\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u306ePatrick Retif\u6c0f\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u3066\u3044\u307e\u3059\u3002\u300c\u5171\u901a\u306e\u696d\u754c\u6a19\u6e96\u304c\u3042\u308c\u3070\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u3068\u533b\u7642\u5f93\u4e8b\u8005\u306f\u3088\u308a\u52b9\u679c\u7684\u304b\u3064\u52b9\u7387\u7684\u306b\u9023\u643a\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308a\u307e\u3059\u3002\u4f01\u696d\u540c\u58eb\u304c\u5354\u529b\u3059\u308b\u3053\u3068\u3067\u3001\u696d\u754c\u5168\u4f53\u3068\u3057\u3066\u30c7\u30b8\u30bf\u30eb\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u3068\u60c5\u5831\u30a2\u30af\u30bb\u30b9\u306b\u8abf\u548c\u304c\u751f\u307e\u308c\u3001\u5404\u793e\u5171\u901a\u306e\u9867\u5ba2\u306b\u9ad8\u54c1\u8cea\u306e\u30b5\u30fc\u30d3\u30b9\u3092\u63d0\u4f9b\u3067\u304d\u308b\u3088\u3046\u306b\u306a\u308b\u306e\u3067\u3059\u3002\u300d<\/p>\n<p>\u8907\u96d1\u306a\u75be\u60a3\u306e\u6cbb\u7642\u306b\u4f7f\u7528\u3059\u308b\u30b9\u30da\u30b7\u30e3\u30ea\u30c6\u30a3\u30c9\u30e9\u30c3\u30b0\u306e\u5e02\u5834\u62e1\u5927\u306b\u3088\u308a\u3001\u533b\u7642\u5f93\u4e8b\u8005\u306f\u500b\u5225\u306e\u72b6\u6cc1\u306b\u5fdc\u3058\u305f\u60c5\u5831\u3092\u9069\u6642\u306b\u5fc5\u8981\u3068\u3059\u308b\u3088\u3046\u306b\u306a\u3063\u3066\u3044\u307e\u3059\u3002\u65b0\u85ac\u304c\u5897\u52a0\u3059\u308c\u3070\u3001\u60a3\u8005\u5bfe\u5fdc\u3092\u5186\u6ed1\u306b\u884c\u3046\u4e0a\u3067\u533b\u7642\u5f93\u4e8b\u8005\u304c\u5fc5\u8981\u3068\u3059\u308b\u60c5\u5831\u91cf\u3082\u305d\u308c\u3060\u3051\u591a\u304f\u306a\u308a\u307e\u3059\u3002\u65b0\u85ac\u3084\u8907\u96d1\u306a\u6cbb\u7642\u6cd5\u306b\u95a2\u3059\u308b\u60c5\u5831\u3092\u533b\u7642\u5f93\u4e8b\u8005\u306b\u63d0\u4f9b\u3059\u308b\u624b\u6bb5\u3068\u3057\u3066\u3001\u30d0\u30a4\u30aa\u533b\u85ac\u54c1\u4f01\u696d\u304c\u30c7\u30b8\u30bf\u30eb\u6280\u8853\u3092\u5c0e\u5165\u3059\u308b\u30e1\u30ea\u30c3\u30c8\u306f\u8a08\u308a\u77e5\u308c\u307e\u305b\u3093\u3002<\/p>\n<p>Align Biopharma\u306f\u3001\u5f53\u9762\u306e\u53d6\u308a\u7d44\u307f\u3068\u3057\u3066\u4e0b\u8a18\u306b\u793a\u3059\u4e8c\u3064\u306e\u696d\u754c\u65b0\u6a19\u6e96\u306e\u7b56\u5b9a\u306b\u30d5\u30a9\u30fc\u30ab\u30b9\u3057\u3001\u30b7\u30fc\u30e0\u30ec\u30b9\u306a\u30c7\u30b8\u30bf\u30eb\u30a8\u30f3\u30b2\u30fc\u30b8\u30e1\u30f3\u30c8\u306e\u5186\u6ed1\u5316\u3068\u533b\u7642\u5f93\u4e8b\u8005\u30a8\u30af\u30b9\u30da\u30ea\u30a8\u30f3\u30b9\u306e\u5358\u7d14\u5316\u3092\u56f3\u308a\u307e\u3059\u3002<\/p>\n<ul>\n<li>\u30a2\u30a4\u30c7\u30f3\u30c6\u30a3\u30c6\u30a3\u7ba1\u7406\uff1a\u8b58\u5225\u30fb\u8a8d\u8a3c\u6a19\u6e96\u3092\u5b9a\u7fa9\u3057\u3001\u533b\u7642\u5f93\u4e8b\u8005\u304c\u30b7\u30f3\u30b0\u30eb\u30b5\u30a4\u30f3\u30aa\u30f3\u3067\u52a0\u76df\u5168\u793e\u306e\u30aa\u30f3\u30e9\u30a4\u30f3\u30b3\u30f3\u30c6\u30f3\u30c4\uff08\u30a6\u30a7\u30d6\u30b5\u30a4\u30c8\u3001\u30dd\u30fc\u30bf\u30eb\u3001\u30d0\u30fc\u30c1\u30e3\u30eb\u30a4\u30d9\u30f3\u30c8\u3001\u30a6\u30a7\u30d3\u30ca\u30fc\u306a\u3069\uff09\u306b\u30a2\u30af\u30bb\u30b9\u3067\u304d\u308b\u3088\u3046\u306b\u3059\u308b\u3002<\/li>\n<li>\u627f\u8a8d\u8a2d\u5b9a\u3068\u30b3\u30df\u30e5\u30cb\u30b1\u30fc\u30b7\u30e7\u30f3\u8a2d\u5b9a\uff1a\u627f\u8a8d\u7ba1\u7406\u304a\u3088\u3073\u30d7\u30ea\u30d5\u30a1\u30ec\u30f3\u30b9\u7ba1\u7406\u306e\u6a19\u6e96\u3092\u5b9a\u7fa9\u3057\u3001\u533b\u7642\u5f93\u4e8b\u8005\u304c\u5404\u793e\u3068\u306e\u9593\u306b\u30b3\u30df\u30e5\u30cb\u30b1\u30fc\u30b7\u30e7\u30f3\u8a2d\u5b9a\u3092\u884c\u3046\u969b\u306e\u6307\u5b9a\u65b9\u6cd5\u3092\u7d71\u4e00\u3059\u308b\u3002<\/li>\n<\/ul>\n<p>Veeva\u306ecommercial cloud strategy\u62c5\u5f53\u30f4\u30a1\u30a4\u30b9\u30d7\u30ec\u30b8\u30c7\u30f3\u30c8\u3001Paul Shawah\u306f\u6b21\u306e\u3088\u3046\u306b\u8ff0\u3079\u307e\u3059\u3002\u300c\u30c7\u30b8\u30bf\u30eb\u6280\u8853\u306b\u3088\u308a\u3001\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u3068\u533b\u7642\u5f93\u4e8b\u8005\u306e\u9023\u643a\u3068\u3084\u308a\u53d6\u308a\u306e\u5f62\u306f\u5927\u304d\u304f\u5909\u308f\u3063\u3066\u304d\u3066\u3044\u307e\u3059\u3002\u9ad8\u5ea6\u306a\u6cbb\u7642\u65b9\u6cd5\u3068\u30c7\u30b8\u30bf\u30eb\u30c1\u30e3\u30cd\u30eb\u304c\u6025\u5897\u3059\u308b\u4e2d\u306b\u3042\u3063\u3066\u306f\u3001\u696d\u754c\u6a19\u6e96\u3092\u8a2d\u3051\u3001\u305d\u308c\u3092\u9806\u5b88\u3059\u308b\u3053\u3068\u3067\u3001\u9069\u5207\u306a\u60c5\u5831\u3092\u7d20\u65e9\u304f\u5165\u624b\u3059\u308b\u969b\u306b\u533b\u5e2b\u3092\u60a9\u307e\u305b\u3066\u3044\u308b\u6570\u3005\u306e\u8ab2\u984c\u3092\u5358\u7d14\u5316\u3067\u304d\u307e\u3059\u3002\u300d<\/p>\n<p>Align Biopharma\u306b\u95a2\u3059\u308b\u8a73\u7d30\u306f<a href=\"http:\/\/www.alignbiopharma.org\/\">AlignBiopharma.org<\/a>\u3092\u3054\u89a7\u304f\u3060\u3055\u3044\u3002\u56e3\u4f53\u306e\u76ee\u7684\u3068\u7b56\u5b9a\u4e2d\u306e\u6a19\u6e96\u5316\u5185\u5bb9\u306b\u3064\u3044\u3066\u7d39\u4ecb\u3057\u3066\u3044\u307e\u3059\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u3010Align Biopharma<\/strong><strong>\u306b\u3064\u3044\u3066\u3011<\/strong><br \/>\nAlign Biopharma\u306f\u8907\u6570\u306e\u5927\u624b\u88fd\u85ac\u4f01\u696d\u304b\u3089\u306a\u308b\u696d\u754c\u6a19\u6e96\u5316\u3092\u63a8\u9032\u3059\u308b\u56e3\u4f53\u3067\u3001\u533b\u7642\u5f93\u4e8b\u8005\u3068\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u4f01\u696d\u3068\u306e\u9023\u643a\u304a\u3088\u3073\u8cea\u306e\u9ad8\u3044\u60a3\u8005\u30b1\u30a2\u306b\u5fc5\u8981\u306a\u533b\u85ac\u54c1\u304a\u3088\u3073\u6cbb\u7642\u6cd5\u306b\u95a2\u3059\u308b\u60c5\u5831\u63d0\u4f9b\u306e\u8fc5\u901f\u5316\u3068\u7c21\u4fbf\u5316\u3092\u76ee\u7684\u3068\u3057\u3066\u3044\u307e\u3059\u3002<br \/>\n\u8a73\u7d30\u306f<a href=\"http:\/\/www.alignbiopharma.org\/\">http:\/\/www.alignbiopharma.org\/<\/a>\u3092\u3054\u53c2\u7167\u304f\u3060\u3055\u3044\u3002<\/p>\n<p>&nbsp;<\/p>\n<p><strong>\u3010\u672c\u4ef6\u306b\u95a2\u3059\u308b\u304a\u554f\u3044\u5408\u308f\u305b\u5148\u3011<\/strong><br \/>\nBarbadora Ink<br \/>\n\u62c5\u5f53\uff1a Lisa Barbadora<br \/>\nTEL\uff1a +1-610-420-3413<br \/>\nE-mail\uff1a\u00a0<a href=\"mailto:lbarbadora@barbadoraink.com\">lbarbadora@barbadoraink.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>2017\u5e741\u670820\u65e5 Align Biopharma Veeva Systems\u3010NYSE:VEEV\u3011(\u672c\u793e : \u30ab\u30ea\u30d5\u30a9\u30eb\u30cb\u30a2\u5dde\u30d7\u30ec\u30b6\u30f3\u30c8\u30f3\u3001\u65e5\u672c\u6cd5\u4eba \u672c\u793e : \u6771\u4eac\u90fd\u6e0b\u8c37\u533a\u3001\u65e5\u672c\u6cd5\u4eba\u4ee3\u8868\u53d6\u7de0\u5f79 : \u5ca1\u6751 \u5d07\u3001\u4ee5\u4e0b V&hellip;<\/p>\n","protected":false},"author":131,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[322],"tags":[],"class_list":["post-39592","post","type-post","status-publish","format-standard","hentry","category-press-release"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/39592"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/comments?post=39592"}],"version-history":[{"count":7,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/39592\/revisions"}],"predecessor-version":[{"id":39606,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/posts\/39592\/revisions\/39606"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/media?parent=39592"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/categories?post=39592"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/jp\/wp-json\/wp\/v2\/tags?post=39592"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}